NEWARK, N.J., United States, September 2024 — BioCentriq, a pioneer in cell therapy contract development and manufacturing, is delighted to announce Syed T. Husain as its new Chief Executive Officer and member of the Board of Directors. With a robust background in CDMO development, Husain brings over two decades of strategic management and operational excellence to BioCentriq.
James Park, Chairman of the Board, expressed confidence in Husain’s ability to navigate BioCentriq through its next growth phase, particularly as the cell and gene therapy sector evolves rapidly. “Syed’s proven leadership in expanding CDMO business will be crucial for BioCentriq as we aim to spearhead manufacturing innovation and manage the clinical to commercial manufacturing of advanced cell therapies,” Park noted.
Syed T. Husain remarked on his new role, “I am thrilled to lead BioCentriq at this pivotal time. We are uniquely positioned to support the next generation of therapies, ensuring they reach the patients who need them most, with a strong focus on driving the approval of new modalities and enhancing our end-to-end manufacturing solutions.”
Under Husain’s leadership, BioCentriq aims to strengthen its market presence and enhance its manufacturing capabilities to support the fast-evolving needs of pharma and biotech customers. This appointment underscores BioCentriq’s commitment to being at the forefront of manufacturing innovation in the cell and gene therapy space.
Founded with the mission to revolutionize cell therapy manufacturing, BioCentriq has emerged as a leader in the development, manufacturing, and release of GMP autologous and allogeneic cell therapies. Operating out of two U.S.-based facilities, BioCentriq combines the agility and innovation of a specialist CDMO with robust corporate backing, including from GC Corporation of South Korea. Specializing in early- to mid-stage therapies, BioCentriq is expanding its scope to offer end-to-end clinical to commercial manufacturing solutions.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
